Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study-Reference-Cited by-同舟云学术

Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study

Published:2022-04-26 Issue:8 Volume:395 Page:933-943
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Gontika Maria,Skarlis Charalampos,Markoglou Nikolaos,Tzanetakos Dimitrios,Vakrakou Aglaia,Toulas Panagiotis,Koutsis George,Evangelopoulos Maria-Eleptheria,Pons Roser,Dardiotis Efthymios,Chrousos George,Dalakas Marinos,Stefanis Leonidas,Anagnostouli Maria^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00210-022-02238-y.pdf

Reference44 articles.

1. Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J (2017) The use of natalizumab in pediatric patients with active relapsing multiple sclerosis: a prospective study. Pediatr Neurol 70:56–60. https://doi.org/10.1016/j.pediatrneurol.2017.01.017

2. Anagnostouli M, Manouseli M, Artemiadis A et al (2014) HLA-DRB1* allele frequencies in pediatric adolescent and adult-onset multiple sclerosis patients, in a Hellenic sample Evidence for new and established associations. J Mult Scler 1:1. https://doi.org/10.4172/2376-0389.1000104

3. Archelos J, Pervitali S, Hartung H (1999) The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 22(1):30–38. https://doi.org/10.1016/s0166-2236(98)01287-9

4. Arnal-Garcia C, García-Montero MR, Málaga I et al (2013) Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol 17(1):50–54. https://doi.org/10.1016/j.ejpn.2012.09.004

5. Banwell B, Reder AT, Krupp L et al (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 28 66(4):472–476. https://doi.org/10.1212/01.wnl.0000198257.52512.1a

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-09

2. Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis;Therapeutic Advances in Neurological Disorders;2023-01

3. First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center;Neurological Sciences;2022-10-05

4. Natalizumab;Reactions Weekly;2022-09-10